AI‑driven antibody developer Earendil Labs licensed payload‑linker technology from WuXi XDC in a partnership with potential value up to approximately $885 million, including upfronts, development and sales milestones, plus tiered royalties. WuXi XDC will support CMC via its WuXiTecan‑2 CRDMO platform while Earendil focuses on development, global regulatory submissions and commercialization. Earendil’s CEO described the deal as a strategic step to scale ADC development using established payload‑linker chemistry and manufacturing logistics. The collaboration follows Earendil’s prior multi‑billion dollar arrangements with Sanofi for bispecific programs, signaling an aggressive externalization strategy. The alliance highlights growing industry interest in pairing AI‑driven discovery with established ADC manufacturing platforms to accelerate translational timelines and reduce technical risk in payload‑linker engineering.